Senate Reform Bill Includes Tax Credit For Dx, Drug-Delivery Investments
This article was originally published in The Gray Sheet
Executive Summary
Companies with 250 or fewer employees would be eligible for a 50% tax credit on 2009-2010 investments in certain diagnostics, drug-delivery devices and pharmaceuticals under a provision in the Senate's health care reform bill
You may also be interested in...
Diagnostics Firms Poised To Gain From Innovation Tax Credit Program
Diagnostics firms stand to benefit most among medical device companies from $1 billion in life sciences innovation tax credits approved earlier this year, according to AdvaMed
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.